Invima lanza alerta sobre el uso de antiinflamatorios en embarazadas: riesgos y recomendaciones
El uso de medicamentos indiscriminados en el embarazo puede generar ciertos riesgos para el feto. El Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Invima) recientemente lanzó una nueva alerta dirigida a la población embarazada del país, específicamente sobre el uso de Antiinflamatorios No Esteroideos (AINEs).
Invima lanza alerta sobre el uso de antiinflamatorios en embarazadas: riesgos y recomendaciones The Invima has issued an alert regarding the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) during pregnancy, particularly after 20 weeks gestation. These medications can cause serious fetal developmental issues, including renal problems and premature closure of the ductus arteriosus. The Invima advises against self-medication with NSAIDs and recommends seeking professional medical attention for pain or inflammation during pregnancy.
- Invima warns pregnant women about the risks of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
- NSAID use before 20 weeks of pregnancy can lead to serious fetal development problems.
- After 20 weeks, NSAIDs pose risks such as oligohydramnios (reduced amniotic fluid), fetal kidney dysfunction, and premature closure of the ductus arteriosus.
- NSAIDs inhibit prostaglandins and tromboxanes by blocking cyclooxygenase (COX) enzymes.
- The FDA recommended avoiding NSAIDs from week 20 onwards in 2020 due to these risks.
- NSAIDs are often available over-the-counter, increasing the risk of unsupervised use by pregnant women.
- NSAIDs are safe and effective for acute pain or inflammation when used under professional supervision.
- Recommendations include avoiding self-medication with NSAIDs, especially from week 29, seeking medical attention for ailments, and informing healthcare providers about all consumed substances during prenatal check-ups.
Write a comment